LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience.

    Rouvinov, Keren / Mazor, Gal / Kozlener, Ella / Meirovitz, Amichay / Shrem, Noa Shani / Abu Saleh, Omar / Shalata, Sondos / Yakobson, Alexander / Shalata, Walid

    Journal of personalized medicine

    2023  Volume 13, Issue 11

    Abstract: In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI's in penile squamous cell carcinoma ( ... ...

    Abstract In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI's in penile squamous cell carcinoma (pSCC) we performed a retrospective observational study. We reviewed electronic medical records of patients with penile squamous cell carcinoma (SCC), diagnosed between January 2020 and February 2023. Nine patients were screened, of whom three were ineligible for chemotherapy and received immunotherapy, cemiplimab, in a first-line setting. Each of the three immunotherapy-treated patients achieved almost a complete response (CR) after only a few cycles of therapy. The first patient had cerebral arteritis during treatment and received a high-dose steroid treatment with resolution of the symptoms of arteritis. After tapering down the steroids dose, the patient continued cemiplimab without further toxicity. The other two patients did not have any toxic side effects of the treatment. To the best of our knowledge, this is the first real world report of near CR with cemiplimab as a first-line treatment in penile SCC.
    Language English
    Publishing date 2023-11-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662248-8
    ISSN 2075-4426
    ISSN 2075-4426
    DOI 10.3390/jpm13111623
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: [TREATMENT OF ONCOLOGY PATIENTS DURING THE CORONA VIRUS ERA].

    Khoury, Rasha / Gorenberg, Miguel / Lazri, Sahar / Amromin, Tatiana / Kozlener, Ella / Agbarya, Abed

    Harefuah

    2020  Volume 159, Issue 12, Page(s) 861–866

    Abstract: Background: Cancer patients are more at risk to contract SARS-CoV-2 and may develop many more severe complications, along with high mortality rates relative to the cancer-free population. The outbreak of the epidemic was characterized by a high rate of ... ...

    Abstract Background: Cancer patients are more at risk to contract SARS-CoV-2 and may develop many more severe complications, along with high mortality rates relative to the cancer-free population. The outbreak of the epidemic was characterized by a high rate of infection from person to person, however medical systems remained fully functional. Following most international guidelines, adaptations were made to the performance level of oncology treatments, and the service was to continue as usual. Moreover, the corona virus epidemic era was characterized by new challenges such as emergency work schedules, additional hygiene measures and social distancing. Furthermore, the medical staff used Personal Protection Equipment and resource preparedness for a larger outbreak and probable collapse of the health system. Therefore, changes have been made in the form and delivery of patient care and treatments. This article presents the work format employed in the Oncology Unit at Bnai Zion Medical Center during the COVID-19 epidemic. The newly adjusted protocol included four areas: staff, patients, infrastructure and malignant disease types.
    MeSH term(s) COVID-19 ; Coronavirus ; Coronavirus Infections ; Humans ; Neoplasms/epidemiology ; Neoplasms/therapy ; SARS-CoV-2
    Language Hebrew
    Publishing date 2020-12-23
    Publishing country Israel
    Document type Journal Article
    ZDB-ID 953872-0
    ISSN 0017-7768
    ISSN 0017-7768
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 291: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments.

    Agbarya, Abed / Sarel, Ina / Ziv-Baran, Tomer / Schwartz, Orna / Shechtman, Yelena / Kozlener, Ella / Khoury, Rasha / Sheikh-Ahmad, Mohammad / Saiegh, Leonard / Swaid, Forat / Ahmad, Asala Abu / Janzic, Urska / Brenner, Ronen

    Diseases (Basel, Switzerland)

    2023  Volume 11, Issue 4

    Abstract: The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the ... ...

    Abstract The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients receiving active anti-neoplastic treatment. A total of 142 patients received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients who received three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients who received two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38-42.12),
    Language English
    Publishing date 2023-09-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720869-2
    ISSN 2079-9721
    ISSN 2079-9721
    DOI 10.3390/diseases11040128
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs.

    Agbarya, Abed / Sarel, Ina / Ziv-Baran, Tomer / Agranat, Sivan / Schwartz, Orna / Shai, Ayelet / Nordheimer, Sharon / Fenig, Shlomit / Shechtman, Yelena / Kozlener, Ella / Taha, Tarek / Nasrallah, Haitam / Parikh, Roma / Elkoshi, Nadav / Levy, Carmit / Khoury, Rasha / Brenner, Ronen

    Cancers

    2021  Volume 13, Issue 16

    Abstract: The BNT162b2 vaccine was shown to be highly effective in reducing the risk of COVID-19 infection in healthy individuals and patients with chronic disease. However, there are little data regarding its efficacy in patients treated for cancer. We analyzed ... ...

    Abstract The BNT162b2 vaccine was shown to be highly effective in reducing the risk of COVID-19 infection in healthy individuals and patients with chronic disease. However, there are little data regarding its efficacy in patients treated for cancer. We analyzed the humoral response following vaccination with the second dose of BNT162b2 in 140 patients with solid malignancies who were receiving anti-cancer therapy at the time of vaccination and 215 participants who had not been diagnosed with cancer. Multivariate analysis was performed, followed by matching the two groups by age, gender and days from vaccination. The humoral response in the cancer patient group was significantly lower than in the non-cancer group: 20/140 seronegative (14.3%) vs. 3/215 (1.4%),
    Language English
    Publishing date 2021-08-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13164191
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top